Research programme: PARP inhibitors - BiPar Sciences

Drug Profile

Research programme: PARP inhibitors - BiPar Sciences

Alternative Names: BSI-101; BSI-401

Latest Information Update: 22 Oct 2010

Price : $50

At a glance

  • Originator BiPar Sciences
  • Developer BiPar Sciences; University of Texas M. D. Anderson Cancer Center
  • Class Benzopyrans; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 22 Oct 2010 Preclinical development is ongoing in USA (PO)
  • 07 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top